Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (617kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-589113
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.58911
Zusammenfassung
Elevated plasma lipoprotein(a) (LPA) levels are recognized as an independent risk factor for cardiovascular diseases. Our knowledge on LPA metabolism is incomplete, which makes it difficult to develop LPA-lowering medications. Nicotinic acid (NA) is the main drug recommended for the treatment of patients with increased plasma LPA concentrations. The mechanism of NA in lowering LPA is virtually ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags